ArticleBMJ public health2026
Implications of the 2025 AHA/ACC hypertension guideline on hypertension prevalence, treatment eligibility and blood pressure control in Nigeria: a cross-sectional comparative study.
Article in BMJ public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The blood pressure (BP) threshold at which pharmacotherapy benefit outweighs the risk of withholding treatment remains dynamic with advancing knowledge. This study explored the implications of the 2025 American Heart Association/American College of Cardiology (AHA/ACC) guideline on hypertension prevalence, treatment eligibility and BP control in Nigeria. Methods: This was a secondary analysis of a population-based cross-sectional hypertension survey in Lagos, Nigeria. Participants were categorised as AHA/ACC 2025, Seventh Report of the Joint National Committee (JNC 7) or known hypertensives on treatment. Demographic characteristics, hypertension staging, pharmacotherapy eligibility, cardiovascular risk profile and target BP control rates were compared across categories (kidney disease-eligibility and Predicting Risk of Cardiovascular Disease Events tool-based eligibility were excluded). Results: Among 3030 participants aged 17-92 years, 2788 (92.0%) met AHA/ACC 2025 criteria, 1340 (44.2%) met JNC 7 criteria and 242 (8.0%) were known treated hypertensives. AHA/ACC 2025 identified a higher proportion of hypertensives aged 20-39 years. Over half of participants in both AHA/ACC 2025 and JNC 7 categories had stage 1 hypertension. Compared with JNC 7, AHA/ACC 2025 increased pharmacotherapy eligibility by 17.2% in males and 18.0% in females, with the largest increments (23.6% and 25.5%) in adults aged <20 and ≥60 years, respectively. Over a third required lifestyle modification alone under both guidelines. Among treated hypertensives, target BP control rate was 19.4% (JNC 7) and 10.7% (AHA/ACC 2025). Conclusions: Application of the 2025 AHA/ACC guideline increased the burden of hypertension and pharmacotherapy eligibility in Nigeria, widening the gap between eligibility and current treatment and control rates. While this reflects earlier identification of hypertension with potential long-term cardiovascular benefit, realising this advantage in low-resource settings will require considering its implications for medicine supply, workforce capacity, and the feasibility of laboratory-based eligibility criteria in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.